BioLineRx (NASDAQ:BLRX – Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Monday, November 23rd. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $0.36 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 23, 2026 at 8:30 AM ET.
BioLineRx (NASDAQ:BLRX – Get Free Report) last released its earnings results on Friday, August 28th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.62). BioLineRx had a negative net margin of 502.08% and a negative return on equity of 34.80%. The firm had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect BioLineRx to post ($1.57) EPS for the current fiscal year and ($1.26) EPS for the next fiscal year.
BioLineRx Trading Down 9.1%
Shares of NASDAQ:BLRX opened at $0.96 on Friday. BioLineRx has a 52-week low of $0.78 and a 52-week high of $3.95. The company has a market capitalization of $4.80 million, a P/E ratio of -0.57 and a beta of 1.64. The company has a 50-day simple moving average of $2.01 and a 200 day simple moving average of $2.62. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.04 and a current ratio of 1.20.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat, BioLineRx has an average rating of “Sell”.
Check Out Our Latest Stock Report on BioLineRx
BioLineRx Company Profile
BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners. Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation.
Featured Stories
- Five stocks we like better than BioLineRx
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
